Key result
High PON2 expression correlates with worse survival in solid tumors but better survival in leukemia.
Why the study?
Recent findings have highlighted the important role of PON2 in protection against oxidative stress, inhibition of apoptosis, and progression of various malignancies, but its expression and intracellular localization across different cancers remain to be characterized.
Observational (n=10,000)
p-value: p=0.02
High PON2 expression correlates with worse prognosis in solid tumors and may protect cancer cells via localization on the nuclear envelope and endoplasmic reticulum.
PON2 belongs to the paraoxonase protein family that consists of lactone hydrolyzing enzymes with different substrate specificities. Unlike other members of the family, PON2 exhibits substantial antioxidant activity, is localized predominantly inside the cell, and is ubiquitously expressed in all human tissues. Previously, it was proffered that defense against pathogens, such as Pseudomonas aeruginosa, is the main function of paraoxonases. However, recent findings have highlighted the important role played by PON2 in protection against oxidative stress, inhibition of apoptosis, and progression of various types of malignancies. In the current study, we performed a bioinformatic analysis of RNA and DNA sequencing data extracted from tumor samples taken from more than 10,000 patients with 31 different types of cancer and determined expression levels and mutations in the PON2 gene. Next, we investigated the intracellular localization of PON2 in multiple cancer cell lines and identified the proteins interacting with PON2 using the LC-MS/MS technique. Our data indicate that a high PON2 expression level correlates with a worse prognosis for patients with multiple types of solid tumors and suggest that PON2, when localized on the nuclear envelope and endoplasmic reticulum, may protect cancer cells against unfavorable environmental conditions and chemotherapy.
No takes yet. Share an insight, caveat, or question.
Shakhparonov et al. (2018) conducted an observational in Cancer (n=10,000). High PON2 expression vs. Low PON2 expression was evaluated on Patient survival (p=0.02). High PON2 expression correlates with a worse prognosis for survival in patients with solid tumors such as liver cancer and glioblastoma, but indicates a better prognosis in leukemia.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: